Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI001 in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
NCT07862010Phase 1Recruiting
- Sponsor
- Hematology Department, 920th Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of GI001 in B-cell non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Hematology Department, 920th Hospital. Primary endpoints: Incidence and severity of adverse events at 2 years, Change from baseline in body temperature at 24 months and 17 more. Started Nov 2025; status: recruiting.
02
Drugs
GI001
03
Conditions
B-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07862010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862010.